GSK in talks to buy cancer biotech Nuvalent for more than $9bn
By
Aanu Adeoye, Oliver Barnes, James Fontanella-Khan
27d ago· 2 min readNews
Source
bskyGSK in talks to buy cancer biotech Nuvalent for more than $9bnft.trib.alDeal would rank as one of UK drugmaker’s biggest as biotech M&A activity accelerates this year
You might also wanna read
Recent moves of note in and around the biotech and pharma industries
nature.com
BioTradingArena: AI Biotech Trading Benchmark with 655 Validated Catalyst Cases
BioTradingArena is a benchmark dataset for AI-driven biotech trading, containing 655 validated biotech catalyst cases with linked clinical t
biotradingarena.com·4mo ago
Goldman Sachs Report Questions Financial Sustainability of Curative Gene Therapies
Goldman Sachs analysts question whether curing patients is a sustainable business model for biotech companies, particularly those developing
cnbc.com·7mo agoAnne Wojcicki Wins Bidding for 23andMe
wsj.com·1y ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.